Introduction {#Sec1}
============

Coronaviruses are enveloped, positive-sense single-stranded RNA viruses belonging to the family *Coronaviridae* \[[@CR1]\]. Their genomes are approximately 30 kb in length, are polycistronic, and have a peculiar transcription mechanism that results in the production of a nested set of subgenomic mRNAs \[[@CR1]\]. Their virions are mainly composed of four structural proteins: nucleocapsid (N), membrane (M), envelope (E), and spike (S) proteins, all of which are essential building blocks for virion formation \[[@CR1]\]. The spike proteins are the most external structures of coronavirus particles, and they are responsible for attachment of the virus to target cells (via specific ligand-receptor interactions) and, consequently, for the initiation of infection \[[@CR1]\].

Coronaviruses are recognized animal and human pathogens \[[@CR2]\]. Up to the end of 2019, there were six coronaviruses known to cause respiratory disease in humans, with varying degrees of severity: human coronavirus (HCoV)-OC43, HCoV-229E, HCoV-NL63, HCoV-HKU1, severe acute respiratory syndrome coronavirus (SARS-CoV), and Middle East respiratory syndrome coronavirus (MERS-CoV) \[[@CR1], [@CR3]\]. MERS-CoV emerged in the Saudi Arabia in 2012 and has since spread to 26 other countries \[[@CR4]\]. Infection is known to cause a wide range of manifestations, varying from asymptomatic to acute respiratory distress syndrome, which can evolve to circulatory collapse, multiorgan failure, and death \[[@CR5]\]. According to the World Health Organizations (WHO), as of the end of November 2019, 2494 laboratory-confirmed human cases have been reported, 858 of which were fatal (34.4% case-fatality rate).

In December 2019, a cluster of cases of atypical pneumonia of unknown etiology in Wuhan, China, attracted global attention \[[@CR6]--[@CR8]\]. A novel coronavirus was isolated from these patients, and named SARS-CoV-2. Infection with this new virus also has a wide range of clinical manifestations, from asymptomatic, to mild fever with dry cough, to severe pneumonia \[[@CR9]\].

In this study, we analyzed the global gene expression of human pulmonary epithelial cells infected with MERS-CoV or SARS-CoV-2 by microarray to understand the pulmonary pathological consequences of infection by these two coronaviruses.

Materials and methods {#Sec2}
=====================

Viruses and cells {#Sec3}
-----------------

The SARS-CoV-2 strain hCoV-19/Korea/CNUHV03/2020 was isolated in our laboratory from human clinical samples collected at the Chungnam National University Hospital (Daejeon, South Korea). Vero cells, cultured in minimal essential medium (MEM) supplemented with 2% fetal bovine serum (FBS), were used in the isolation protocol. The MERS-CoV strain EMC2012 was kindly provided by Dr. Bart Haagmans and Dr. Ron Fouchier (Erasmus Medical Center). All experimental procedures involving potential contact with MERS-CoV or SARS-CoV-2 were conducted in a biosafety level 3 (BSL3) laboratory, certified by the Korean government.

Primary human pulmonary epithelial cells were purchased from ScienCell research laboratories (Carlsbad, CA, USA) and maintained in alveolar epithelial cell medium (AEpicM) supplemented with 10% FBS.

Determination of viral titers by plaque assay {#Sec4}
---------------------------------------------

Primary human pulmonary epithelial cells, grown in 6-well plates, were infected with MERS-CoV or SARS-CoV-2 at an MOI of 0.01, and their culture supernatants were collected on days 2, 4 and 6 postinfection. Viral titers were measured by plaque assay. Briefly, serial tenfold dilutions of the collected culture supernatants were added to confluent Vero cell cultures and incubated for 4 h. Afterwards, cultures were overlaid with 1% electrophoretic agar (LPS Solution, Korea) and incubated for 4 days. Cells were then stained with 0.1% crystal violet (Sigma-Aldrich, St. Louis, MO, USA) in a 37% formaldehyde solution, and plaque-forming units (pfu) were measured.

Analysis of gene expression patterns by microarray {#Sec5}
--------------------------------------------------

Primary human pulmonary epithelial cells, grown in 6-well plates, were infected with MERS-CoV or SARS-CoV-2 at an MOI of 2 for 12 hours when viral particles were produced in the infected cells. Uninfected cells were maintained under the same conditions as negative controls. Total RNA was then isolated using an RNeasy Mini Kit (QIAGEN, Hilden, Germany). The purified RNAs from infected and uninfected cells were analyzed using microarray (Affymetrix Human 2.0 ST array). This analysis was performed commercially (ebiogen, Seoul, South Korea).

RNA quality was assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, USA), and the quantity was determined by ND-1000 spectrophotometer (NanoDrop Technologies, USA).

RNA samples were used as input in the Affymetrix procedure as recommended by the manufacturer (<http://www.affymetrix.com>). Briefly, total RNA from each sample was converted to double-stranded cDNA using a random hexamer incorporating a T7 promoter. Amplified RNA (cRNA) was then generated from the double-stranded cDNA template in an *in vitro* transcription (IVT) reaction and purified using an Affymetrix sample cleanup module. cDNA was regenerated in a random-primed reverse transcription reaction using a dNTP mix containing dUTP. The cDNA was then fragmented by UDG and APE 1 restriction endonucleases and end-labeled in a terminal transferase reaction incorporating a biotinylated dideoxynucleotide. Fragmented end-labeled cDNA was hybridized to the Affymetrix arrays for 16 h at 45 °C and 60 rpm as described in the Gene Chip Whole Transcript (WT) Sense Target Labeling Assay Manual (Affymetrix). After hybridization, the chips were stained using streptavidin phycoerythrin (SAPE), washed in a GeneChip Fluidics Station 450 (Affymetrix), and scanned by using a GeneChip Array Scanner 3000 7G (Affymetrix).

After the final wash and staining step, the Affymetrix array was scanned using an Affymetrix Model 3000 G7 scanner, and the image data were extracted using Affymetrix Command Console software 1.1. The raw.cel file generated by the above procedure contained expression intensity data and was used for the next step. Expression data were generated by Transcriptome Analysis Console 4.0.1. For normalization, the RMA (robust multi-average) algorithm implemented in the Transcriptome Analysis Console software was used.

Ethics statement {#Sec6}
----------------

Clinical sample collection from patients was approved by the CNU hospital ethics committee. The samples were collected with the consent of the patients.

Results {#Sec7}
=======

Viral infectivity in primary human pulmonary epithelial cells {#Sec8}
-------------------------------------------------------------

To evaluate if there were differences in the infectivity of MERS-CoV or SARS-CoV-2, we infected primary human pulmonary epithelial cells at an MOI of 0.01 and subsequently measured viral titers by plaque assay. Viral growth was similar. The mean viral titers of lung cells infected with MERS-CoV were 2 × 10^5^, 9 × 10^5^, and 9.8 × 10^5^ pfu after 2, 4, and 6 days of infection, respectively. The mean viral titers determined for SARS-CoV-2 were 2.2 × 10^5^, 8.5 × 10^5^, and 9.5 × 10^5^ at the same time points (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Virus growth in primary human lung epithelial cells infected with MERS-CoV and SARS-CoV-2. Primary human pulmonary alveolar cells were infected with SARS-CoV-2 or MERS-CoV at an MOI of 0.01. Viral titers were measured in Vero cells by plaque assay on days 2, 4 and 6 p.i. Data are the mean of three experiments with standard deviations

Global gene expression in primary human pulmonary epithelial cells {#Sec9}
------------------------------------------------------------------

To investigate the impact of MERS-CoV and SARS-CoV-2 infection on global gene expression patterns in primary human lung cells, we infected them with each of these viruses at an MOI of 2, extracted total RNA, and performed a microarray analysis. Uninfected cells processed under the same conditions were used to define the baseline. Overall, the number of differentially expressed genes was higher in MERS-CoV-infected cells than in SARS-CoV-2-infected cells. Out of a total of 44,556 genes analyzed, 127 were differentially expressed in human lung cells infected with MERS-CoV, whereas 50 were differentially expressed in SARS-CoV-2-infected cells (Fig. [2](#Fig2){ref-type="fig"}A, C, and D). Interestingly, our convergent analysis showed that the expression of only eight genes was modulated by both coronaviruses: matrix metallopeptidase 3 (MMP3), oligodendrocyte myelin glycoprotein (OMG), CC chemokine ligand 20 (CCL20), follicular dendritic cell secreted protein (FDCSP), C-X-C ligand 5 (CXCL5), CXCL6, CXCL8 and interleukin-33 (IL-33). The differential gene expression patterns showed similar profiles in human lung cells infected by either MERS-CoV or SARS-CoV-2 (Fig. [2](#Fig2){ref-type="fig"}B). Most of the proteins encoded by these genes belong to distinct families and consequently have distinct functions, such as the proteolytic breakdown of extracellular matrix proteins (MMP3) \[[@CR10]\], the maintenance of the structural integrity of the myelin sheath (OMG) \[[@CR11]\], the direction of protein transport (FDCSP) \[[@CR13]\], the chemoattraction of lymphocytes and neutrophils (CCL20, CXCL5, CXCL6 and CXCL8) \[[@CR12], [@CR14]--[@CR16]\], or regulation of immune responses (IL-33) \[[@CR17]\].Fig. 2Heat maps and fold change of differentially expressed genes in primary human lung epithelial cells infected with MERS-CoV or SARS-CoV-2. Total RNA was collected from primary human lung epithelial cells infected with MERS-CoV or SARS-CoV-2 at 12 hours p.i. The purified RNA was used for microarray analysis using a human DNA chip. **A.** The number of differentially expressed genes with more than a twofold change in expression in human lung cells compared to those in uninfected human lung cells. **B.** Description of genes commonly modulated in human lung cells infected with MERS-CoV and SARS-CoV-2. **C.** Heat map of all genes with more than a twofold change in expression in human lung cells infected with MERS-CoV compared to those in uninfected human lung cells. **D.** Heat map of all genes with more than a twofold change in expression in human lung cells infected with SARS-CoV-2 compared to those in uninfected human lung cells

To better understand the gene expression differences in primary human pulmonary epithelial cells infected by MERS-CoV or SARS-CoV-2, we further limited our analysis and looked at genes related to cell damage, antiviral defense, immunity (*senso lato*), and inflammation (Table [1](#Tab1){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"} and Supplementary Figs. S1-S4). Out of 4443 genes, 24 and 16 were differentially expressed in cells infected with MERS-CoV and SARS-CoV-2, respectively (˃ 2-fold increase compared to uninfected cells) (Fig. [3](#Fig3){ref-type="fig"}).Table 1Gene descriptionsGene symbolGene IDDescriptionBDKRB1NM_000710Bradykinin receptor B1BDKRB2NM_000623Bradykinin receptor B2BIRC3NM_001165Baculoviral IAP repeat containing 3C3NM_000064Complement component 3CCL11NM_002986Chemokine (C-C motif) ligand 11CCL2NM_002982Chemokine (C-C motif) ligand 2CCL20NM_001130046Chemokine (C-C motif) ligand 20CD200NM_001004196CD200 moleculeCLDN1NM_021101Claudin 1CSF3NM_000759Colony-stimulating factor 3CXCL1NM_001511Chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha)CXCL5NM_002994Chemokine (C-X-C motif) ligand 5CXCL6NM_002993Chemokine (C-X-C motif) ligand 6CXCL8NM_000584Chemokine (C-X-C motif) ligand 8DDIT3NM_001195053DNA-damage-inducible transcript 3EDNRBNM_000115Endothelin receptor type BGBP4NM_052941Guanylate binding protein 4GREM1NM_001191322Gremlin 1, DAN family BMP antagonistHPRNM_020995Haptoglobin-related proteinICAM1NM_000201Intercellular adhesion molecule 1IGKV1D-16OTTHUMT00000323144Immunoglobulin kappa variable 1D-16IL32NM_001012631Interleukin 32IL33NM_001199640Interleukin 33IL7RNM_002185Interleukin 7 receptorKDRNM_002253Kinase insert domain receptorMAOBNM_000898Monoamine oxidase BMMP3NM_002422Matrix metallopeptidase 3PDCD1LG2NM_025239Programmed cell death 1 ligand 2PREX1NM_020820Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1PTGS2NM_000963Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)SEMA7ANM_001146029Semaphorin 7A, GPI membrane anchor (John Milton Hagen blood group)SLC27A2NM_001159629Solute carrier family 27 (fatty acid transporter), member 2TNFAIP3NM_001270507Tumor necrosis factor, alpha-induced protein 3TNFSF18NM_005092Tumor necrosis factor (ligand) superfamily, member 18Fig. 3Heat maps and fold change of genes involved in antiviral activity, cell damage, immune response, and inflammatory response in primary human lung epithelial cells infected with MERS-CoV or SARS-CoV-2

Concerning antiviral-defense-related genes, only six were identified as differentially expressed, out of a total of 596. Of these, TNFAIP3 and guanylate-binding protein 4 (GBP4) showed the highest variation in their expression level, in cells infected with MERS-CoV (4.50-fold) and SARS-CoV-2 (4.14-fold) (Supplementary Fig. S1). Importantly, GBP4 is known to be directly involved in protective immunity against viruses \[[@CR18], [@CR19]\].

With respect to cell-damage-related genes, out of a total of 1115, nine and five were found to be differentially expressed in human lung cells infected with MERS-CoV and SARS-CoV-2, respectively compared to uninfected cells. Of these, tumor necrosis factor α-induced protein 3 (TNFAIP3) and prostaglandin-endoperoxide synthase 2 (PTGS2) were the ones with the highest variation in their expression level, in cells infected with MERS-CoV (4.50-fold) and SARS-CoV-2 (3.23-fold) (Supplementary Fig. S2). While TNFAIP3 is known to inhibit NF-κB activation and TNF-mediated apoptosis, PTGS2 is involved in the conversion of arachidonic acid to prostaglandin H2 \[[@CR20]\].

Additionally, looking at immune responses as a whole (Supplementary Fig. S3), out of a total of 2044 genes involved in immunity, 20 and 10 genes were found to be differentially expressed in human lung cells infected with MERS-CoV and SARS-CoV-2, respectively compared to uninfected cells. CXCL1 and CXCL6 showed the highest variation in their expression level, in each of these contexts (4.69-fold and 8.63-fold, respectively). Both CXCL1 and CXCL6 are known to be important chemotactic factors affecting the migration of neutrophils and granulocytes \[[@CR21], [@CR22]\].

Out of 688 genes involved in inflammatory responses (Supplementary Fig. S4), 12 and 11 genes were differentially expressed in human lung cells infected with MERS-CoV and SARS-CoV-2, respectively, compared to the basal conditions. Because inflammation and immunity are known to overlap, CXCL6 appeared again as the gene with the highest variation in its expression level, in both MERS-CoV- and SARS-CoV-2-infected cells (8.63-fold and 6.50 fold, respectively).

Discussion {#Sec10}
==========

Highly pathogenic coronaviruses such as MERS-CoV, SARS-CoV, and the newly identified SARS-CoV-2 have the potential to cause severe pneumonia in humans. In this study, we used a microarray assay to analyze the global gene expression of human pulmonary epithelial cells infected with MERS-CoV or SARS-CoV-2 to investigate the impact of coronavirus infection on lung cells and, consequently, on the respiratory system as a whole.

Interestingly, we found that, out of the 44,566 human genes analyzed, more were differentially expressed in cells infected with MERS-CoV than in cells infected with SARS-CoV-2 (127 vs. 50 genes). These results may be related to the observation that MERS-CoV infections tend to be more severe than those caused by the new SARS-CoV-2. Based on the currently available data, the mortality rates for MERS-CoV and SARS-CoV-2 infections are approximately 36%, and less than 10%, respectively.

However, when we limited the analysis to inflammatory-response-related genes, the number of differentially expressed genes was similar in *in vitro* MERS-CoV and SARS-CoV-2 infections (12 and 11 genes, respectively). This may suggest that both infections lead to similar local inflammatory responses, which is not unexpected, considering that the two viruses are closely related and that inflammation is dependent on innate (nonspecific) immunity. On the other hand, when we looked at immune-response-related genes, the cells infected with MERS-CoV had twice as many differentially expressed genes as the cells infected with SARS-CoV-2 (20 vs. 10). These results suggest that the two infections lead to different immune responses, which are in line with previously published data. A recent study revealed that immunity-related gene expression patterns in a human lung cancer cell line (Calu-3) infected with MERS-CoV or SARS-CoV were different \[[@CR23]\]. While the expression of genes coding for IL-1β, IL-6 and IL-8 was shown to be significantly upregulated in cells infected with MERS-CoV compared to cells infected with SARS-CoV, the reverse was observed for the expression of genes coding for TNF-α, IFN-β and IP-10 (up to 30 h postinfection) \[[@CR23]\]. In fact, even in the context of SARS-CoV-2 infection alone, cytokine and chemokine plasma profiles have been shown to differ between patients with different levels of disease severity \[[@CR24]\]. While IL-1β, IL-1RA, IL-8, IL-9, basic FGF, GMCSF, IFN-γ, IP-10, MIP-1β, PDGF, and VEGF concentrations were comparable between ICU- (intensive care unit) and non-ICU-admitted COVID-19 patients, the concentrations of IL-1, IL-7, IL-10, GCSF, IP-10, MCP1, MIP-1α, and TNF-α levels were higher in ICU-admitted patients than in non-ICU-admitted patients \[[@CR24]\].

We found that CXCL6, which is a chemoattractant for neutrophilic granulocytes \[[@CR15], [@CR22]\], was the most strongly upregulated inflammatory gene in human pulmonary epithelial cells infected with SARS-CoV-2. CXCL6 may be involved in the development of severe pneumonia in humans infected with SARS-CoV-2 by recruiting inflammatory leukocytes into human lungs.

We used the primary human pulmonary epithelial cells to investigate changes in gene expression when SARS-CoV-2 infects lung cells. Considering that SARS-CoV-2 infects human lungs, our model might reflect some of the changes that occur in lung cells of humans infected with SARS-CoV-2. However, further *in vivo* study is needed to confirm our data, using human ACE (angiotensin converting enzyme)-2 transgenic mice infected with SARS-CoV-2.

In this study, we used the laboratory MERS-CoV strain EMC2012 because we did not have a recent MERS-CoV isolate. Further study may be needed to investigate gene modulation in lung cells using a more recent MERS-CoV strain.

In conclusion, the greater number of differentially expressed genes in primary pulmonary epithelial cells infected with MERS-CoV than in those infected with SARS-CoV-2 may explain the why MERS-CoV infections more frequently lead to worse outcomes than SARS-CoV-2 infections.
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